tbuckley/cabot-search huggingface dataset:
1503TiP A phase II study of cemiplimab plus BNT116 versus cemiplimab alone in first-line treatment of patients with advanced non-small cell lung cancer with PD-L1 expression ≥50%
Authors: M.M. Awad, Y. Hao, S. Li, M. Kaul, F. Seebach, P. Goncalves, P. Brück, P. Rietschel
Journal: Annals of Oncology (2023)
1616O Nab-paclitaxel plus gemcitabine versus modified FOLFIRINOX or S-IROX in metastatic or recurrent pancreatic cancer (JCOG1611, GENERATE): A multicentred, randomized, open-label, three-arm, phase II/III trial
Authors: A. Ohba, M. Ozaka, G. Ogawa, T. Okusaka, S. Kobayashi, T. Yamashita, M. Ikeda, I. Yasuda, K. Sugimori, N. Sasahira, K. Ikezawa, I. Miki, N. Okano, N. Mizuno, M. Furukawa, H. Shirakawa, Y. Sano, H. Katayama, J. Furuse, M. Ueno
Journal: Annals of Oncology (2023)
1617P PRODIGE 29-UCGI 26 (NEOPAN): Quality of life results of a phase III randomised trial comparing chemotherapy with folfirinox (FFX) or gemcitabine (gem) in locally advanced pancreatic carcinoma (LAPC)
Authors: M.P. Ducreux, R. Desgrippes, Y. Rinaldi, F. Di Fiore, R. Guimbaud, L. Evesque, J-B. Bachet, P. Vanelslander, T. Lecomte, O. Capitain, A. Parzy, M. Bolliet, P.L. Etienne, J. Forestier, F. El Hajbi, A.L. Bignon Bretagne, V. Ly Lebrun, N. De Sousa Carvalho, M. Texier, O. Bouche
Journal: Annals of Oncology (2023)
1636P Circulating tumor DNA (ctDNA) profile in patients (pts) with pancreatic cancer (PC): A multicenter experience and challenges for clinical application
Authors: L. Ghiglione, F.J. Muñoz i Carrillo, F.M. Esposito, D. Pesantez Coronel, M.D. Delcuratolo, R. Garcia-Carbonero, C. Fabregat-Franco, G. Alonso, T. Macarulla, L. Ceniceros Paredes, M. Ponz-Sarvise, L. Visa Turmo, A.M. López Muñoz, B. Pastor, A. Indacochea, M.P. Vicente Lazcano, F.N. Riva, A. Prat, I. Victoria, T. Sauri Nadal
Journal: Annals of Oncology (2023)
1618P Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion positive (NRG1+) pancreatic ductal adenocarcinoma (PDAC)
Authors: A. Schram, T. Macarulla, J. Cleary, C. Neuzillet, D. Arnold, K.A. Reiss, T. Bekaii-Saab, J. Rodon, K. Goto, S.Y. Rha, M. Duruisseaux, N. Leighl, B.A. Weinberg, M.N. Al-Hallak, A.K. Joe, S. Adeyemi, E. Wasserman, K-J. Koeman, A. Drilon, E.M. O'Reilly
Journal: Annals of Oncology (2023)
1506TiP A single-arm, phase II study of amivantamab (AMI), lazertinib (L) and pemetrexed (P) for first-line treatment of recurrent/metastatic non-small cell lung cancers (NSCLCS) with epidermal growth factor receptor mutations in Exons 19 or 21 (EGFR 19/21): AMIGO 1 (LACOG0821)
Authors: W. Nassib William Junior, L.H. de Lima Araújo, F.A.F. Da Silva, A.C. Gelatti, E.H.C. Silva, F.J. Silva Melo Cruz, G. De Castro, K.C. Abdalla, M. Zereu, P.R. De Marchi, S. Bandeira Aleixo, S. Cunha Sousa Oliveira, T. Cardoso Motta, R. de Jesus, T.F. Rebelatto
Journal: Annals of Oncology (2023)
1622P D-1553 in patients with KRAS G12C mutated advanced pancreatic cancer (pca)
Authors: S. Kondo, D. Yan, V. Ganju, G. Richardson, X. Hou, J. Shan, X. Liu, Y. Zhang, X. Xie, Z. Xiang, Z. Shi, Y. Wang, L. Zhang, N. Yamamoto
Journal: Annals of Oncology (2023)
1634P Extensive molecular profiling of KRAS wild-type versus KRAS mutant pancreatic ductal adenocarcinoma on 233 patients
Authors: J. Lena, M. Alamé, A. Italiano, I. Soubeyran, L. Blouin, E. Khalifa, S. Cousin, S. Pernot, L-J. Palmieri
Journal: Annals of Oncology (2023)
1625P Multicenter, randomized, parallel group, phase II study to establish the efficacy and safety of CBP501, cisplatin, and nivolumab for ≥ third-line treatment of patients with exocrine pancreatic cancer and WBC &lt;10,000/mm3
Authors: T. Enzler, A. Nguyen, J. Misleh, V.J. Cline, M.E. Johns, N. Shumway, A.S. Paulson, R. Siegel, T. Larson, W. Messersmith, D. Richards, J. Chaves, E. Pierce, M. Zalupski, V. Sahai, D. Orr, T. Kawabe, S.A. Ruste, A. Haun
Journal: Annals of Oncology (2023)
1502TiP A phase I/IIa trial of ChAdOx1 and MVA vaccines against MAGE-A3 and NY-ESO-1
Authors: F. Blackhall, L. Moliner, A. Samson, K. Franks, I. Karydis, D. Joseph-Pietras, O. Frank, H. Lavender, M. Jannoo, M. Marshall, P. Motteram, B.J. van den Eynde, C. Leung, A. Hill, M.R. Middleton, N.A. Coupe, N. Steele, J. Spicer, P.H. Shaw, S.N. Symeonides
Journal: Annals of Oncology (2023)
1628P Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Preliminary results from a multi-cohort, multi-center phase II trial (ALTER-G-001)
Authors: J. Wu, J. Zhang, C. Zhou, J. Yan, L. Zhu, J. Jiang, C. Wang, J. Chen, Z. Han, C. Wang, M. Yong, X. Tang, Z. Qin, X. Wei, C. Shangguan
Journal: Annals of Oncology (2023)
1627P First-line (1L) fuzuloparib plus mfolfirinox followed by maintenance fuzuloparib in patients (pts) with unresectable locally advanced or metastatic (LA/M) pancreatic cancer (PC): A phase Ib study
Authors: X. Yu, Y. Mou, X. Chen, C. Liu, X. Zhang, J. Xu, J. Zhang, S. Shi, M. Wei, J. Li, R. Liu, S. Gao, L. Xu, Z. Sheng, J. Lian, Q. Shi
Journal: Annals of Oncology (2023)
1504TiP HARMONi: Randomized, double-blind, multi-center, phase III clinical study of ivonescimab or placebo combined with pemetrexed and carboplatin in patients with EGFR-mutant locally advanced or metastatic non-squamous NSCLC who have progression following EGFR-TKI treatment
Authors: W. Fang, F. Cappuzzo, J.W. Goldman, Y. Zhao, Y. Huang, I. Anderson, J. Remon Masip, W. Li, M. Xia, J. Li, D. James, L. Styles, H.L. West, L. Zhang
Journal: Annals of Oncology (2023)
1641P ABCG transporter and SRPK1 kinase inhibition of chemotherapy resistance: A phase Ib clinical trial of safety and maximum tolerated dose for SCO-101 in combination with gemcitabine and nab-paclitaxel in inoperable pancreatic cancer
Authors: M. Ladekarl, S. Shim, T.J. Ettrich, A. Kestler, P. Pfeiffer, L.S. Tarpgaard, A. Reinacher-Schick, A-L. Kraeft, J. Stenvang, A. Zurlo, N. Lindland Roest
Journal: Annals of Oncology (2023)
1626P A novel endoscopic ultrasound guided extended-release siRNA implant targeting KRASG12D/V in localized pancreatic cancer
Authors: A.M. Varghese, T. Golan, M. Schattner, C. Ang, M. Gutierrez, M. Passhak, R. Geva, N. Yarom, R. Ligresti, I. Khamaysi, M.S. Bhutani, S. Matalon, O. Pollack-Shragai, D.M. Rom, M. Shirvan, M. Javle, E.M. O'Reilly
Journal: Annals of Oncology (2023)
1507TiP Phase Ib multicenter study of trastuzumab deruxtecan (T-DXd) and immunotherapy with or without chemotherapy in first-line treatment of patients (pts) with advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) and HER2 overexpression (OE): DESTINY-Lung03
Authors: D. Planchard, J.R. Brahmer, J.C-H. Yang, H.R. Kim, R.K. Li, J-Y. Han, D.L. Cortinovis, Y. Runglodvatana, E. Nakajima, A. Ragone, M. Winter, M. Gustavson
Journal: Annals of Oncology (2023)
1631P Phase I study of endoscopic ultrasound (EUS)-guided NBTXR3 delivery activated by radiotherapy (RT) for locally advanced or borderline resectable pancreatic cancer (LAPC or BRPC)
Authors: G. Fuentes, M.J. Rodriguez, A. Al-Sharfeen, M.H. Katz, N. Ikoma, C-W.D. Tzeng, M.J. Overman, S. Pant, M.S. Lee, R. Wolff, M. Javle, C.M. Taniguchi, E.B. Ludmir, P. Das, A.C. Koong, O.I. Vivar, S. Liu, E.P. Tamm, M.S. Bhutani, E.J. Koay
Journal: Annals of Oncology (2023)
1632P Organoids as tools for functional precision oncology in advanced pancreatic cancer
Authors: A. Boileve, J. Cartry, N. Goudarzi, S. Bedja, J. Mathieu, A. Mouawia, C. Nicotra, V. Boige, D. Malka, M. Valery, A.A. Tarabay, M.A. Bani, P. Dartigues, T. de Baere, A. Italiano, M. Gelli, C. Smolenschi, M.P. Ducreux, A. Hollebecque, F. Jaulin
Journal: Annals of Oncology (2023)
1638P The prognostic and predictive role of class III β-tubulin and hENT1 expression in patients with advanced pancreatic ductal adenocarcinoma
Authors: T.K. Sahin, A. Isik, D.C. Guven, F. Ceylan, B. Babaoglu, A. Akyol, S. Yalcin, O. Dizdar
Journal: Annals of Oncology (2023)
1635P Germline pathogenic variants of cancer predisposition genes in a multicentre Italian cohort of pancreatic ductal adenocarcinoma patients
Authors: G. Orsi, C. Carconi, P. Ghiorzo, L. Pastorino, M. Chiaravalli, E. Barbieri, G. Giordano, P. Carrera, A. Puccini, M.S. Sciallero, L. Salvatore, L. Cortesi, M. Landriscina, E. Allavena, C. Pirrone, G. Tortora, L. Archibugi, M. Macchini, M. Falconi, M. Reni
Journal: Annals of Oncology (2023)
1619P Health-related quality of life with nalirifox versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): EORTC QLQ-C30 results from the NAPOLI 3 trial
Authors: D. Melisi, T. Macarulla, C. de la Fouchardiere, R.A. Pazo Cid, S. Chandana, A. Dean, I. Kiss, W. Lee, T.O. Goetze, E. Van Cutsem, A.S. Paulson, T. Bekaii-Saab, S. Pant, R. Hubner, Z. Xiao, L. Zhang, F.M. Benzaghou, E.M. O'Reilly, Z.A. Wainberg
Journal: Annals of Oncology (2023)
1505TiP TROPION-Lung07: A phase III trial of datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) as first-line (1L) therapy in advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC) with PD-L1 expression
Authors: I. Okamoto, S. Kuyama, N. Girard, S. Lu, F.A. Franke, E. Pan, N. Ren, A. Chen, E. Oputa, A.E. Lisberg
Journal: Annals of Oncology (2023)
1624P Predictive factors for treatment success of second-line Nal-IRI/5-FU/FA in patients with metastatic pancreatic ductal adenocarcinoma (PDAC) (AIO-PAK-0216)
Authors: M.P. Lutz, N. Ansorge, G. Barmashenko, C. Burkart, T. Decker, T.J. Ettrich, L. Fischer von Weikersthal, T. Geer, A. Gerhardt, S. Hoefling, L. Jacobasch, M. Karthaus, M.P. Koenigsmann, T. Leidig, M. Schulte, N. Schulte, A. Schwarzer, G.M. Siegler, D.T. Waldschmidt, S. Raeth
Journal: Annals of Oncology (2023)
1510TiP Efficacy study of osimertinib in treatment-naïve patients with EGFR mutant non-small cell lung cancer (NSCLC) according to TP53 mutational status (TEMPLE-2/NCT05785208)
Authors: A. Vitale, S. Pilotto, F. Monaca, L. Belluomini, G. Valente, L. Giannone, R. Berardi, P. Bironzo, A. Ceribelli, D. Galetta, A.J. Gelibter, A. Lugini, M. Roselli, M. Tiseo, V. Scotti, D. Giannarelli, A. Scarpa, M. Milella, G. Tortora, E. Bria
Journal: Annals of Oncology (2023)
1621P Efficacy and safety of erdafitinib in adults with pancreatic cancer and prespecified fibroblast growth factor receptor alterations (FGFRalt) in the phase II open-label: Single-arm RAGNAR trial
Authors: S. Pant, D. Arnold, J. Tabernero, Y. Loriot, G. Folprecht, G.M. Haag, D. Palmer, H. Prenen, J. Coward, I. Lugowska, J-C. Goeminne, A. Cervantes, M. Gutierrez, H. Sweiti, C. Hammond, S. Najmi, S. Thomas, S. Triantos, L. Crow, M.H.H. Schuler
Journal: Annals of Oncology (2023)
1630P Phase I/Ib study of SHP2-ERK inhibition in KRASm pancreatic cancer (SHERPA trial) and preclinical identification of potential resistance markers
Authors: A.C. Kanhailal, A. Mulero-Sánchez, J.E. Knikman, A. Bosma, R. Bernards, A.D.R. Huitema, E.E. Voest, S. Mainardi, F. Opdam
Journal: Annals of Oncology (2023)
1623P Pelareorep (pela) + atezolizumab (atezo) and chemotherapy in first-line (1L) advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) patients: Results from the GOBLET study
Authors: D. Arnold, E. Goekkurt, A. Stein, U.M. Martens, J. Chater, G. Ungerechts, H. Loghmani, M. Coffey, R. Trauger, T.C. Heineman
Journal: Annals of Oncology (2023)
1620P A phase II study of perioperative nalirifox in patients with resectable pancreatic ductal adenocarcinoma (rPDAC): Survival update and biomarkers analysis of the NITRO trial
Authors: D. Melisi, V. Merz, F. Fazzini, S. Pietrobono, C. Zecchetto, G. Malleo, L. Landoni, A. Quinzii, S. Casalino, None C. pesoni, M. Gaule, L. Casetti, M. D'Onofrio, A. Gabbrielli, L. Bernardoni, S. Milleri, G. Butturini, A. Scarpa, R. Salvia, C. Bassi
Journal: Annals of Oncology (2023)
1633P Development and clinical validation of news transcriptomic tools for predicting the response to individual drug of the mfolfirinox regimen in patients with pancreatic ductal adenocarcinoma
Authors: N. Fraunhoffer, C. Teyssedou, M. Bigonnet, P. Pessaux, J.L. Iovanna, N. Dusetti
Journal: Annals of Oncology (2023)
1509TiP The 1825-EORTC, ALKALINE: Activity of lorlatinib based on ALK resistance mutations on blood in ALK positive NSCLC patients previously treated with second generation ALK inhibitor
Authors: L. Mezquita, E. Xenophontos, Y. Pretzenbaher, C. Sureda, E. Nadal, K. Al-Rabi, G. Rousseau Bussac, S. Ponce Aix, I.G. Sullivan, A. Calles Blanco, N. Cloarec, J. De Langen, T. Berghmans, R. Descourt, L. Hendriks, P. Garrido Lopez, A. Helland, E. Carcereny, B. Besse, A-M.C. Dingemans
Journal: Annals of Oncology (2023)
1508TiP The 1920-EORTC-BIORADON study: Molecular characterization of non-small cell lung cancer (NSCLC) and indoor radon exposure in Europe
Authors: L. Mezquita, F. Turrisi, M.E. Mauer, C. Mallien, E. Xenophontos, C. Olungu, G. Katanga, A-T. Mota, F. Borges, K. Amrane, I.G. Sullivan, B. Rubio-Viqueira, J. Raimbourg, L. Greillier, J. Rogado, G. Rousseau Bussac, S. Aso, M. Morfouace, A-M.C. Dingemans, B. Besse
Journal: Annals of Oncology (2023)
1498P HGF/MET pathway is associated with poor efficacy of Immune checkpoint inhibitors (ICIs) in advanced-stage NSCLC
Authors: A. Akli, P. Takam Kamga, A.E. Costantini, C.G. Kotokpo Youkou, C. Julie, C. Capron, C. Dumenil, J. Dumoulin, V. Giraud, M. Glorion, E. Longchampt, J-F. Emile, E. Giroux-Leprieur
Journal: Annals of Oncology (2023)
1422P Comprehensive genomic profiling (CGP) changes management and improves survival in patients with advanced non-small cell lung cancer (aNSCLC)
Authors: G. Simon, A. Berry, B. Bapat, J. Law, C. Sweetnam, H. Mohammed, A. McBratney, M. Izano, M. Scannell Bryan, S. Spencer, D. Hostin, B. Schroeder, P.G. Febbo
Journal: Annals of Oncology (2023)
1431P The nNGM Preclinical Platform: Preclinical research to generate evidence for patients with non-small cell lung cancer harboring variants of unknown significance
Authors: M. Ziegler, C. Albers-Leischner, L. Salgueiro, N. Khoury, Y. Sharapova, F.C. Saalfeld, C. Wenzel, H. Scharpenseel, C. Schmidt, J. Naveja-Romero, S. Meemboor, A. Hillmer, L. Nogova, M. Wermke, J. Wolf, S. Diederichs, T. Brummer, R. Büttner, M. Janning, S. Loges
Journal: Annals of Oncology (2023)
1457P Oligometastatic non-small cell lung cancer: Impact of local and systemic treatment approaches on clinical outcome
Authors: M. Wiesweg, C. Küter, J. Schnorbach, J. Keyl, T. Plönes, M. Metzenmacher, J. Cvetkovic, W.E.E. Eberhardt, F. Oezkan, D. Theegarten, A. Stenzinger, K. Darwiche, F.J.F. Herth, S. Bölükbas, H. Winter, F. Weykamp, M. Stuschke, M. Thomas, M.H.H. Schuler, P. Christopoulos
Journal: Annals of Oncology (2023)
1442P DURATION: A multicenter randomized phase II trial investigating sequential mono- (mCTX) or doublet-chemotherapy (dCTX) followed by durvalumab (D) in older or frail patients with advanced non-small cell lung cancer (NSCLC)
Authors: J.B. Kuon, M. Blasi, K. Kokowski, M. Faehling, W. Schuette, D.C.C. Christoph, M. Kimmich, W. Engel-Riedel, J.R. Fischer, M. Lehmann, M. Ulmer, P. Schuett, N. Moosmann, C. Meyer zum Büschenfelde, F. Griesinger, M. Schneider, R. Behnisch, A. Stenzinger, P. Christopoulos, M. Thomas
Journal: Annals of Oncology (2023)
1417P Change in healthcare resource use and associated costs of patients with metastatic lung cancer between 2013 and 2019: An observational study from the French national claims database
Authors: C. Chouaid, C. Marchal, M. Apert, L. Bensimon, V. Guimard, M. Née, M. Belhassen, G. de Pouvourville, J-Y. Blay
Journal: Annals of Oncology (2023)
1444P Sintilimab with two cycles nab-paclitaxel / platinum as first line therapy for advanced squamous non-small-cell lung cancer: The final analysis and biomarker results
Authors: H. Wang, M. Zhang, G. Zhang, Y. Niu, G. Zhang, Y. Ji, X. Yan, Q. Wang, X. Jing, J. Wang, Z. Ma
Journal: Annals of Oncology (2023)
1452P Factors associated with real-world (rw) outcomes among pts with metastatic NSCLC (mNSCLC) receiving select immuno-oncology (IO) regimens: CORRELATE
Authors: S.V. Liu, R.J-B. Salomonsen, I. Diaz Perez, A. Wang, L. Cai, J. Schmidt, S. Sadow, S. Peters
Journal: Annals of Oncology (2023)
1458P Pucotenlimab (HX008) - humanized anti-PD-1 monoclonal antibody plus pemetrexed and platinum as first-line treatment for advanced non-squamous non-small-cell lung cancer (nsqNSCLC): A single-arm multicenter phase II study
Authors: C. Zhou, L. Wang, Y. Yu, L. Cao, J. Fang, X. Li, Y. Ge, B. Cao, X. Chen, P. Pan, L. Wu
Journal: Annals of Oncology (2023)
1449P The preliminary data from a single-arm, open-label, multicenter phase II clinical trial: KN046 combined with axitinib as first-line (1L) treatment for NSCLC
Authors: Y. Zhao, Y. Huang, W. Fang, Y. Yang, J. Shi, H. Zhao, X. Meng, L. Zhang, A. Liu, T. Xu, Y. Liu, N. Wang, L. Zhang
Journal: Annals of Oncology (2023)
1424P Outcome of thromboembolic events and its influence on survival time of advanced NSCLC patients receiving antiangiogenic therapy
Authors: W-F. Ou, P-Y. Liao, Y-W. Hsu, K.C. Chen, K-H. Hsu, Y-H. Huang, J-S. Tseng, G-C. Chang, T-Y. Yang
Journal: Annals of Oncology (2023)

Antiangiogenetic therapy and lung cancer, per se, are associated with an increased risk of thromboembolic (TE) events. We aim to evaluate the influence of TE on the outcome of advanced non-small cell lung cancer (NSCLC) patients receiving antiangiogenic therapy. This retrospective cohort study included advanced NSCLC patients receiving antiangiogenic therapy, including bevacizumab and ramucirumab, from March 2013 to May 2021 at Taichung Veterans General Hospital. All TE were confirmed by objective image studies. We evaluated the prevalence, pattern, treatment, and outcome of TE and its influence on survival time. A total of 427 patients were included. Of them, 345 (80.8%) received bevacizumab, 24 (5.6%) received ramucizumab, and 58 (13.6%) received both. The overall prevalence of TE was 10.1% (n = 43). Deep vein thrombosis (DVT) was the most common TE (n = 20), followed by pulmonary embolism (PE) (n = 14), combined PE and DVT (n = 6), and cerebral vascular accidents (n = 3). Among them, 46.2% of DVT did not occur in the typical lower extremities. Two patients died of TE, which presented with massive middle cerebral artery territory infarction. Among patients with continuous use or reuse of antiangiogenetic therapy, 18.2% had recurrent TE events. At TE, 28 patients experienced progressive disease (TE with PD), while tumor status remained stable in another 15 patients (TE without PD). The post-TE survival of patients without and with PD was 8.9 months (95% CI 3.9-13.9) vs. 2.2 months (95% CI 0.1-4.3), P = 0.012. As compared with patients without TE (31.4 months [95% CI 27.1-35.7]), TE with PD patients experienced a significantly shorter overall survival (20.1 months [95% CI 15.5-24.6]), but TE without PD patients had comparable survival time (32.7 months [95% CI 7.4-28.1]) (P = 0006). Multivariate analysis suggested that the use of hormone analog and proteinuria independently predicted a higher TE prevalence among TE with PD patients (aOR 2.79 [95% CI 1.13=6.92]; P = 0.027) and TE without PD patients (aOR 4.30 [95% CI 1.13-16.42]; P = 0.033), respectively. Owing to the different influences on the survival time and risk factors, TE with PD and TE without PD may be two different disease entities.
1448P First-line nivolumab (NIVO) plus ipilimumab (IPI) with two cycles of chemotherapy in patients with metastatic non-small cell lung cancer (NSCLC): Results from an interim analysis of the non-interventional FINN study
Authors: J.B. Kuon, E. von der Heyde, S. Wilop, D.M. Behringer, W. Blau, G. Huebner, D. Flieger, H. Forstbauer, M. Groschek, H-E. Laack, H. Mueller-Huesmann, C. Schumann, D. Waldenberger, S. Gütz
Journal: Annals of Oncology (2023)
1420P Real-life management of octogenarians with NSCLC in a French nationwide cohort
Authors: R. Corre, A-C. Neidhart, J.B. Auliac, J. Pinsolle, S. Hominal, P.A. Renault, P. Brun, S. Martinez, E. Lecuyer, R. Haouachi, A. Turlotte, Y. Duval, P-A. Hauss, L. Thirard, P. Dumont, S. Bordier, C. Locher Genty, F. Bigot, L. Stoven, D. Debieuvre
Journal: Annals of Oncology (2023)
1435P Clinical and molecular study with digital support of advanced non-small cell lung cancer patients: SNF-CLIMEDIN, a prospective randomized Hellenic Cooperative Oncology Group (HeCOG) study: Interim analysis
Authors: H. Linardou, T. Kosmidis, K. Papadopoulou, N. Korfiatis, S. Lampaki, E. Fountzilas, A. Psyrri, A. Vagionas, A.N. Christopoulou, E. Samantas, I. Athanasiadis, G. Mountzios, N.G. Tsoukalas, J.I. Sgouros, A. Koutras, D. Bafaloukos, C.G. Panopoulos, G. Fountzilas, P.A. Kosmidis
Journal: Annals of Oncology (2023)
1446P Preliminary efficacy and safety of rilvegostomig (AZD2936), a bispecific antibody targeting PD-1 and TIGIT, in checkpoint inhibitor (CPI)-pretreated advanced/metastatic non-small-cell lung cancer (NSCLC): ARTEMIDE-01
Authors: M. Brandão, J.T.J.N. Hiltermann, E. Wauters, B.J. Solomon, E. Castanon Alvarez, E. Felip, E.H. Gort, H. Izumi, D-W. Kim, L. Paz-Ares, K.S. Rohrberg, L. Steinbusch, T. Yoshida, H. Chen, S. Colebrook, I. Achour, M. Origuchi, F. Aroldi, B.C. Cho
Journal: Annals of Oncology (2023)
1453P Trends in treatment regimens and survival in the use of immune checkpoint inhibitors for lung cancer treatment in the Netherlands from 2016-2020
Authors: E. Suazo Zepeda, M.A. Heuvelmans, M.J. Aarts, W.J. Maas, P.C. Vinke, J.T.J.N. Hiltermann, G.H. de Bock
Journal: Annals of Oncology (2023)
1447P IMscin001 part 2 updated results: Efficacy, safety, immunogenicity and patient-reported outcomes (PROs) from the randomised phase III study of atezolizumab (atezo) subcutaneous (SC) vs intravenous (IV) in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)
Authors: M. Burotto, Z. Zvirbule, R. Alvarez, B. Chewaskulyong, L.A. Herraez Baranda, E. Shearer-Kang, X. Liu, N. Tosti, A.Y. Castro Sanchez, J. Zanghi, E. Felip
Journal: Annals of Oncology (2023)
1418P Impact of TTFields therapy on global and functional health-related quality of life (HRQoL) in metastatic non-small cell lung cancer (mNSCLC) from the pivotal LUNAR study
Authors: R. Kotecha, T.A. Leal, R. Raumlau, L. Zhang, J. Milanowski, M. Cobo Dols, J. Roubec, L.B. Petruzelka, L. Havel, S. Kalmadi, J.P. Ward, Z.G. Andric, T. Berghmans, G. Kloecker, R. Panikkar, J.G. Aerts, M. Pless, R. Greil, W. Akerley, C.J. Langer
Journal: Annals of Oncology (2023)
1433P CNS efficacy of atezolizumab, bevacizumab, carboplatin and paclitaxel in patients with non-small cell lung cancer and actionable mutations
Authors: M. Rathbone, C. O'Hagan, A. Khan, T. Cook, S. Rose, J. Heseltine, M. Howell, H. Wong, C. Escriu
Journal: Annals of Oncology (2023)
1430P Excellent performance of a fast and fully-automated RNA based genefusion assay conducted on a large fusion positive non-small cell lung cancer cohort within a multicenter study
Authors: A. Hartmann, A. Hirschmann, P. Hofman, A. Concha, S. Mrabet-Dahbi, P. Vannuffel, E. Watkin, M. Putzova, S. Scarpino, A. Cayre, P. Martin, L.C. Melchior
Journal: Annals of Oncology (2023)
1439P Brain radiotherapy combined with camrelizumab and platinum-based chemotherapy as first-line treatment for advanced NSCLC with brain metastases: A multicenter, open-label, single-arm, phase II study
Authors: Y. Fan, Y. Xu, Z. Huang, Y. Xu, L. Sheng, H. Li, H. Lu, K. Chen, S. Yu, L. Gong, N. Han, X. Xu, J. Qin, F. Xie, W. Hong, D. Huang, J. Chen
Journal: Annals of Oncology (2023)
1437P Clinical and economic burden of tissue re-biopsy (TRB) vs. tissue followed by liquid biopsy (TFLB) in metastatic non-small cell lung cancer (mNSCLC) patients
Authors: N.M. Engel-Nitz, A. Shah, J. Apple, S. Aslam, L. Le, M. Terpenning
Journal: Annals of Oncology (2023)

demographic factors influenced platform engagement, highlighting the significance of digital initiatives for patient-centered NSCLC care.
1445P A randomized phase III trial on Pembrolizumab Alone versUs pembrolizumab-chemotherapy in first LInE NSCLC (PAULIEN), results of the interim analysis
Authors: I. Houda, E.B. Ulas, S.M.S. Hashemi, A. Becker, H.M.A. Daniels, S. Tarasevych, E. Looysen, P. Kunst, A. Moons-Pasic, N. Thönissen, J.M.W. van Haarst, P. van Tilburg, B. van der Maat, N. Barlo, M. Disselhorst, V. van Diepen, M. Tiemessen, M. van Laren, J. Veltman, I. Bahce
Journal: Annals of Oncology (2023)